Olanzapine: a critical review of recent literature

Bibliography

• KAPUR S, ZIPURSKY RB, REMINGTON G: Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry (1999) 156:286–293.
   PubMed Web of Science ®Google Scholar
• KAPUR SJ, ZIPURSKY R, JONES C, REMINGTON G, HOULE S: Relationship between dopamine D2 occpancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry (2000) 157:514–520.
   PubMed Web of Science ®Google Scholar
• CHONG SA, REMINGTON G: Plasma olanzapine and clinical response. J. Clin. Psychopharmacol (1999) 19:192–194.
   PubMed Web of Science ®Google Scholar
• BARTZOKIS G: Biological underpinnings of treatment resistance in schizophrenia: an hypothesis. Psychopharmacol Bull. (2003) 37(4):4–7.
   Google Scholar
• REINKE A. MARTINS MR, LIMA MA, MOREIRA JC, DAL-PIZZOL F, QUEVEDO J: Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain. Neurosci. Lett. (2004) 372(1-2):157–160.
   PubMed Web of Science ®Google Scholar
• WAKE CG, MAHADIK SP, CHIU F: Atypical neuroleptics stimulate neurogenesis in adult rat brain. J. Neurosci. Res. (2002) 69:72–79.
   PubMed Web of Science ®Google Scholar
• KODAMA M, FUJIOKA T, DUMAN RS: Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol. Psychiatry (2004) 56(8):570–580.
   PubMed Web of Science ®Google Scholar
• •Important study of neurogenesis in the rat brain.
   Google Scholar
• BERTOLINO A, CAFORIO G, BLASI G et al.: Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am. J. Psychiatry (2004) 161(10):1798–1805.
   PubMed Web of Science ®Google Scholar
• •An intriguing investigation of the interaction between genes, brain function and medication performance.
   Google Scholar
• LANG DJ, KOPALA LC, VANDORPE RA et al.: Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia. Am. J. Psychiatry (2004) 161(10):1829–1836.
   PubMed Web of Science ®Google Scholar
• TOLLEFSON GD, BEASLEY CM, TRAN PV et al.: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry (1997) 154:457–465.
   PubMed Web of Science ®Google Scholar
• TOLLEFSON GD, SANGER TM: Negative symptoms: a path-analytic approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine. Am. J. Psychiatry (1997) 154:466–474.
   PubMed Web of Science ®Google Scholar
• KOPELOWEIZ A, ZARATE R, TRIPODIS K et al.: Differential efficacy of olanzapine for deficit and for nondeficit negative symptoms in schizophrenia. Am. J. Psychiatry (2000) 157:987–993.
   PubMed Web of Science ®Google Scholar
• ROSENHECK R, PERLICK D, BINGHAM S et al.: Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. /AMA (2003) 290(20):2693–2702.
   PubMed Web of Science ®Google Scholar
• •This is an important study conducted in the Veteran's Affairs healthcare system.
   Google Scholar
• TOLLEFSON GD, SANGER TM, LU Y et al.: Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch. Gen. Psychiatry (1998) 55:250–258.
   PubMed Web of Science ®Google Scholar
• MELTZER HY, ALPHS L, GREEN Al et al.: International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry (2003) 60(1):82–91.
   Google Scholar
• SHARMA T, ANTONOVA L: Cognitive function in schizophrenia: deficits, functional consequences, and future treatment. Psych. Clin. N America (2003) 26:25–40.
   PubMed Web of Science ®Google Scholar
• PURDON SE, JONES BD, STIP E: Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. J. Psychiatry (2002) 159:1018–1028.
   PubMed Web of Science ®Google Scholar
• BILDER RM, GOLDMAN RS, VOLAVKA J et al.: A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J. Clin. Psychopharmacol (2003) 23(6):582–594.
   PubMed Web of Science ®Google Scholar
• HARVEY PD, GREEN MF, KEEFE RS, VELLIGAN DI: Cognitive functioning in schizophrenia a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J. Clin. Psychiatry (2004) 65(3):361–372.
   PubMed Web of Science ®Google Scholar
• WAGNER M, QUEDNOW BB, WESTHEIDE J, SCHLAEPFER TE, MATER W, KUHN KU: Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine versus amisulpride. Neuropsychopharmacol. (2005) 30(2):381–390.
   PubMed Web of Science ®Google Scholar
• LITTRELL KH, PETTY RG, HILLIGOSS NM, KIRSHNER NM, KIRSHNER CD: Improvement in social cognition in patients with schizophrenia associated with treatment with olanzapine. Schizophr. Res. (2004) 66(2-3):201–202.
   PubMed Web of Science ®Google Scholar
• LINDENMAYER JP, CZOBOR P, VOLAVKA J et al.: Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. Clin. Psychiatry (2004) 65(4):551–556.
   PubMed Web of Science ®Google Scholar
• TRAN PV, DELLVA MA, TOLLEFSON GD et al.: Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br. J. Psychiatry (1998) 172:499–505.
   PubMed Web of Science ®Google Scholar
• BEASLEY CM, SUTTON VK, HAMILTON SH et al.: A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J. Clin. Psychopharmacol (2003) 23(6):582–594.
   PubMed Web of Science ®Google Scholar
• LEUCHT S, BARNES T, KISSLING W et al.: Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am. J. Psychiatry (2003) 160:1209–1222.
   PubMed Web of Science ®Google Scholar
• DOSSENBACH M, EROL A, MAHFOUD KM et al.: Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. j Clin. Psychiatry (2004) 65(3):312–321.
   PubMed Web of Science ®Google Scholar
• LAMBERT M, HARO JM, NOVICK D et al.: Olanzapine versus other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study. Acta Psychiatr. Scand. (2005) 111(3):232–243.
   PubMed Web of Science ®Google Scholar
• •This is one of the large effectiveness studies in schizophrenia.
   Google Scholar
• CIUDAD A, MONTES JM, OLIVARES JM, GOMEZ JC, EFESO STUDY GROUP: Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study. Eur. Psychiatry (2004) 19(0:358–365.
   PubMedGoogle Scholar
• HAMILTON SH, REVICKI DA, EDGELL ET et al.: Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomized clinical trial. Pharmacoeconomics (1999) 15(5):469–80.
   Google Scholar
• REVICKI DA, GENDUSO LA, HAMILTON SH et al.: Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Quell. Life Res. (1999) 8(5):417–426.
   PubMed Web of Science ®Google Scholar
• SILVA DE LIMA M, DE JESUS MARI J, BREIER A et al.: Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics. J. Clin. Psychiatry. (2005) 66(7):831–838.
   Google Scholar
• NABER D, KAROW A, LAMBERT M: Subjective well-being under the neuroleptic treatment and its relevance for compliance. Acta Psychiatr. Scand. Suppl. (2005) 427:29–34.
   Google Scholar
• NABER D, RIEDEL M, KLIMKE A et al: Randomized double blind comparison of olanzapine versus clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr. Scand. (2005) 111(2):106–115.
   PubMed Web of Science ®Google Scholar
• TRAN PV HAMILTON SH, KUNTZ AJ, POTVIN JH, ANDERSEN SW, BERASLEY C JR: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders./ Clin. Psychopharmacol. (1997) 17:407–418.
   PubMed Web of Science ®Google Scholar
• CONLEY RR, MAHMOUD R: A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am. J. Psychiatry (2001) 158:765–774.
   PubMed Web of Science ®Google Scholar
• SIMPSON GM, GLICK ID, WEIDEN PJ, ROMANO SJ, SIU CO: Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am. J. Psychiatry. (2004) 161(10):1837–1847.
   PubMed Web of Science ®Google Scholar
• BREIER A, BERG PH, THAKORE DN et al.: Olanzapine versus ziprasidone: results of the 28-week double-blind study in patients with schizophrenia. Am. J. Psychiatry (In press).
   Google Scholar
• KINON BJ, LIPKOVICH I, EDWARDS SB et al.: Improvement of comorbid depression with olanzapine versus ziprasidone treatment in patients with schizophrenia or schizoaffective disorder. Presentation at the International Congress on Schizophrenia Research (ICOSR), Savannah GA, April (2005).
   Google Scholar
• MCQUADE RD, STOCK E, MARCUS R et al.: A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J. Clin. Psychiatry. (2004) 65\(Suppl. 18):47–56.
   Google Scholar
• KINON BJ, AHL J, STAUFFER HILL AL, BUCKLEY PF: Dose reponse and atypical antipsychotics in schizophrenia. CNS Drugs (2004) 18(9):597–616. Erratum in CNS Drugs (2004) 18(14):1052.
   Google Scholar
• CITROME L, JAFFE A, LEVINE D: Dosing of second generation antipsychotics in a large state hospital system. Int. J. Neuropsychopharmacol (2004) 7(51):437.
   Google Scholar
• •An interesting analysis of dosing trends with SGAs.
   Google Scholar
• Choosing the right dose of an atypical antipsychotic: art or science? Symposium at the American Psychiatric Association Annual Meeting, May (2004).
   Google Scholar
• CONLEY RR, TAMMINGA CA, BARTKO JJ et al.: Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am. J. Psychiatry (1998) 155:914–920.
   PubMed Web of Science ®Google Scholar
• MARTIN J, GOMEZ J, GARCIA-BERNARDO E et al.: Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the study of olanzapine in treatment-refractory schizophrenia. J. Clin. Psychiatry (1997) 58:479–483.
   Google Scholar
• LINDENMAYER JP, VOLAVKA J, LIEBERMAN Jet al.: Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open label, prospective trial. J. Clin. Psychopharmacol (2001) 21:448–453.
   Google Scholar
• DURSUN SM, GARDNER DM, BIRD DC, FLINN J: Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case series outcome study. Can. J. Psychiatry (1999) 44:701–704.
   PubMed Web of Science ®Google Scholar
• VOLAVKA J, CZOBOR P, SHEITMAN B et al.: Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am. J. Psychiatry (2002) 159:255–262.
   PubMed Web of Science ®Google Scholar
• •This is an important comparative study of SGAs in refractory patients.
   Google Scholar
• WRIGHT P, BIRKETT M, DAVID SR et al.: Double-blind, placebo-controlled comparison of intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am. J. Psychiatry (2001) 158(7):1149–1151.
   PubMed Web of Science ®Google Scholar
• BREIER A, MEEHAN K, BIRKETT M et al.: A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine in haloperidol in the treatment of acute agitation in schizophrenia. Arch. Gen. Psychiatry (2002) 59(5):441–448.
   PubMed Web of Science ®Google Scholar
• BAKER RW, KINON BJ, MAGUIRE GA et al.: Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation./ Clin. Psychopharmocol. (2003) 23(4):342–348.
   Google Scholar
• KINON BJ, AHL J, ROTELLI MD, MCMULLEN E: Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. Am. J. Emerg-. Med. (2004) 22(3):181–186.
   PubMed Web of Science ®Google Scholar
• SWANSON JW, SWARTZ MS, ELBOGEN EB: Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophr. Bull (2004) 30(1):3–20.
   PubMed Web of Science ®Google Scholar
• •An interesting analysis of a naturalistic follow-up study of offending among a high-risk schizophrenia population.
   Google Scholar
• VOLAVKA J, CZ OBOR P, NOLAN K et al.: Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J. Clin. Psychopharmacol (2004) 24(2):225–228.
   PubMed Web of Science ®Google Scholar
• KINON BJ, HILL AL, LIU J, KOLLACK -WALKERS: Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia. Int. J. Neuropsychopharmacol (2003) 6(2):97–102.
   PubMed Web of Science ®Google Scholar
• LIU-SIEFERT H, HOUSTON J, HILL A, KINON B: Improvement of influences on medication adherence I noncompliant patients with schizophrenia treated with orally disintegrating olanzapine tablets. Presentation at the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December (2004).
   Google Scholar
• BRADFORD D, PERKINS D, LIEBERMAN J: Pharmacological management of first-episode schizophrenia and related nonaffective psychoses. Drugs (2003) 63(21):2265–2283.
   PubMed Web of Science ®Google Scholar
• SANGER TM, LIEBERMAN JA, TOHEN M et al.: Olanzapine versus haloperidol treatment in first-episode psychosis. Am. J. Psychiatry (1999) 156:79–87.
   PubMed Web of Science ®Google Scholar
• BOBES J, GIBERT J, CIUDAD A et ell.: Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic patients. Prog-. Neuropsychopharmacol Biol. Psychiatry (2003) 27(3):473–481.
   Google Scholar
• LIEBERMAN JA, TOLLEFSON G, TOHEN M et al.: HGDH Study Group. Comparative efficacy and safety of atypical and conventional antypsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am. J. Psychiatry (2003) 160(8):1396–1404.
   Google Scholar
• •This is an important, initial publication on a major first episode study.
   Google Scholar
• LEIBERMAN JA, TOLLEFSON GD, CHARLES C et al.: Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry (2005) 62(4):361–370.
   PubMed Web of Science ®Google Scholar
• MALLA A, NORMAN R, SCHOLTEN D et al.: A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition. Psychiatry Res. (2004) 129(2):159–169.
   PubMed Web of Science ®Google Scholar
• STAHL SM: Prophylactic antipsychotics:do they keep you from catching schizophrenia? brainstorms/. Clin. Psychiatry (2004) 65(11):1445–1446.
   PubMed Web of Science ®Google Scholar
• •A provocative brief review of an emerging area of research.
   Google Scholar
• MILLER TJ, ZIPURSKY RB, PERKINS D et al.: The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the `prodromar sample. Schizophr. Bull. (2003) 61(1):19–30.
   Google Scholar
• MCGLASHAN TH, ZIPURSKY RB, PERKINS DA, ADDINGTON J: Olanzapine for treatment of schizophrenia prodrome: 2-year results of a randomized placebo-controlled study. Schizophr. Res. (2004) 67:164.
   Web of Science ®Google Scholar
• SANDERS RD, MOSSMAN D: An open trial of olanzapine in patients with treatment-refractory psychoses. Clin. Psychopharmacol (1999) 19:62–66.
   PubMed Web of Science ®Google Scholar
• BITTER I, DOSSENBACH MR, BROOKS S et al.: Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia olanzapine for refractory schizophrenia. Int. Clin. Psychopharmacol (2004) 28(1):173–180.
   Google Scholar
• MORESCO RM, CAVALLARO R, MESSA C et al.: Cerebral D2 and 5-HT2 receptor occupancy in schizophrenic patients treated with olanzapine or clozapine. Psychopharmacol. (2004) 18(3):355–365.
   Web of Science ®Google Scholar
• BUCHANAN RW, BALL MP, WEINER E et al.: Olanzapine treatment of residual positive and negative symptoms. Am. J. Psychiatry (2005) 162(1):124–129.
   PubMed Web of Science ®Google Scholar
• BOTTS S, LITTRELL R, DE LEON J: Variables associated with high olanzapine dosing in a state hospital. J. Clin. Psychiatry (2004) 65(8):1138–1143.
   PubMed Web of Science ®Google Scholar
• MAZEH D, MELAMED Y, WEIZMAN k D2 antagonist augmentation in patients with a partial response to atypical antipsychotics. Can. J. Psychiatry (2004) 49(4):281–282.
   PubMed Web of Science ®Google Scholar
• DUGGAL HS: Aripiprazole-olanzapine combination for treatment of schizophrenia. Can. J. Psychiatry (2004) 49(2):151.
   PubMed Web of Science ®Google Scholar
• KOTLER M, STROUS RD, REZNIK I et al.: Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology. Int. Clin. Psychopharmacol (2004) 19(1):23–26.
   PubMed Web of Science ®Google Scholar
• CASEY DE, DANIEL D, WASSEFF AA et al.: Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology (2003) 28(1):182–192.
   PubMed Web of Science ®Google Scholar
• CASEY DE, HERESCO-LEVY U, ERMILOV M, LICHTENBERG P, BAR G, JAVITT DC: High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol. Psychiatry (2004) 55(2):165–171.
   PubMed Web of Science ®Google Scholar
• VIETA E, GOIKALEA M: A typical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disorder (2005) 7(4):21–33.
   PubMedGoogle Scholar
• TOHEN M, GOLDBERG JF, GONZALEZ-PINTO ARRILLAGA AM et al.: A 12-week, double-blind comparison of olanzapine versus haloperidol in the treatment of acute mania. Arch. Gen. Psychiatry (2003) 60(12):1218–1226.
   Google Scholar
• TOHEN M, VIETA E, CALABRESE J et al.: Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry (2003) 60(11):1079–1088.
   PubMed Web of Science ®Google Scholar
• ZAJECKA JM, WEISLER R, SACHS G, SWANN CA, WOZNIAK P, SOMMERVILLE KW: A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J. Clin. Psychiatry (2002) 63(12):1148–1155.
   PubMed Web of Science ®Google Scholar
• TOHEN M, BAKER RW, ALTSHULER LL et al.: Olanzapine versus divalproex in the treatment of acute mania. Am. J. Psychiatry (2002) 159(0:1011–1017.
   PubMedGoogle Scholar
• VIETA E, CALABRESE JR, HENNEN J et al.: Comparison of rapid-cycling and non-rapid-cycling bipolar I manic patients during treatment with olanzapine: analysis of pooled data. J. Clin. Psychiatry (2004) 65(10):1420–1428.
   PubMed Web of Science ®Google Scholar
• AWAD AG, VORUGANTI LN: Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs (2004) 18(13):877–93.
   PubMed Web of Science ®Google Scholar
• TOLLEFSON GD, BEASLEY CM, TAMURA RN et al.: Double-blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am. J. Psychiatry (1997) 154:1248–1254.
   PubMed Web of Science ®Google Scholar
• LITTRELL KH, JOHNSON CG, LITTRELL S et al.: Marked reduction of tardive dyskinesia with olanzapine. Arch. Gen. Psychiatry (1998) 55:279–280.
   PubMed Web of Science ®Google Scholar
• KINON BJ, JESTE DV, KOLLACK-WALKER S, STAUFFER V, LIU-SEIFERT H: Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog-. Neuropsychopharmacol. Biol. Psychiatry (2004) 6:985–996.
   Google Scholar
• CORRELL CV, LEUCHT S, KANE JM et al.: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry (2004) 161(3):414–425.
   PubMed Web of Science ®Google Scholar
• NEWCOMER JW: Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs (2005) 19\(Suppl. 1):1–93.
   Google Scholar
• ALLISON DB, MENTORE JL, MOONSEONG H et al.: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry (1999) 156:193–210.
   Web of Science ®Google Scholar
• AMERICAN DIABETES ASSOCIATION; AMERICAN PSYCHIATRIC ASSOCIATION; AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, NORTH AMERICAN ASSOCIATION FOR THE STUDY OF OBESITY. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care (2004) 27:596–601.
   PubMedGoogle Scholar
• •An important consensus statement on the risk profile of each SGA.
   Google Scholar
• CASEY DE, HAUPT DW, NEWCOMER JW et al.: Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J. Clin. Psych. (2004) 65\(Suppl. 7):4–18.
   Google Scholar
• •An excellent review of a complex, topical area of research.
   Google Scholar
• KINON BJ, KAISER CJ, AHMED S et al.: Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J. Clin. Psychopharmacol. (2005) 25(3):255–8.
   PubMed Web of Science ®Google Scholar
• BAPTISTA T, ZARATE J, JOOBER R et al.: Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr. Drug Targets (2004) 5(3):279–299.
   PubMed Web of Science ®Google Scholar
• WEIDEN P, LOEBEL A, YENG R, LELSVITZ H: Course of weight and metabolic benefits 1 year after switching to ziprasidone. Schizophr. Bull. (2005) 31(2):572–573.
   Web of Science ®Google Scholar
• BUSE JB, CAVAZZONI P, HORNBUCKLE K, HUTCHINS D, BREIER A. JOVANOVIC L: A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J. Clin. Epidemiol. (2003) 56(2):164–170.
   Google Scholar
• KORO CE, FEDDER DO, EITALIEN GJ et al.: Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. Br. Med. J. (2002) 325(7358):243.
   PubMed Web of Science ®Google Scholar
• CITROME L, JAFFE A, LEVINE J, ALLINGHAM B, ROBINSON J: Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr. Serv. (2004) 55(9):1006–1013.
   PubMed Web of Science ®Google Scholar
• SERNYAK MJ, ALACON RD et al.i Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am. J. Psychiatry (2002) 159:561–566.
   PubMed Web of Science ®Google Scholar
• MARDER SR, ESSOCK SM, MILLER AL et al.: Physical health monitoring of patients with schizophrenia. Am. J. Psychiatry (2004) 161:1334–1349.
   PubMed Web of Science ®Google Scholar
• •This is a thoughtful synthesis of the risk-benefit profile of antipsychotic therapy. The recommendation for assessment and monitoring seem reasonable.
   Google Scholar
• BREIER A, KIRKWOOD SC, FU DJ et al.: Genome-wide association study for olanzapine - emergent weight gain. Neuropsychopharmaca (2004) 29:S109.
   Web of Science ®Google Scholar